Healius
Market Cap
AU$1.9b
Last Updated
2019/10/23 10:31 UTC
Data Sources
Company Financials +
Executive Summary
Healius Limited provides various services and facilities to general practitioners, specialists, dentists, IVF specialists, and other healthcare professionals operating in the bulk billing and private billing sector in Australia.
Snowflake
Fundamentals
Reasonable growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Healius's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-1.0%
HLS
-1.1%
AU Healthcare
-1.0%
AU Market
1 Year Return
6.2%
HLS
17.9%
AU Healthcare
12.2%
AU Market
Return vs Industry: HLS underperformed the Australian Healthcare industry which returned 19.8% over the past year.
Return vs Market: HLS underperformed the Australian Market which returned 11.9% over the past year.
Shareholder returns
| HLS | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.0% | -1.1% | -1.0% |
| 30 Day | -4.6% | 3.0% | -1.4% |
| 90 Day | 5.5% | -0.7% | -1.9% |
| 1 Year | 8.9%6.2% | 21.5%17.9% | 18.8%12.2% |
| 3 Year | -10.1%-19.8% | 11.1%0.9% | 38.4%19.8% |
| 5 Year | -18.3%-32.3% | 42.3%22.3% | 50.8%16.5% |
Price Volatility Vs. Market
How volatile is Healius's share price compared to the market and industry in the last 5 years?
Simply Wall St News
9 months ago | Simply Wall St
Why You Should Care About Healius Limited’s (ASX:HLS) Low Return On CapitalValuation
Is Healius undervalued compared to its fair value and its price relative to the market?
33.44x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: HLS (A$3.08) is trading above our estimate of fair value (A$1.32)
Significantly Below Fair Value: HLS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: HLS is poor value based on its PE Ratio (33.4x) compared to the Healthcare industry average (19.1x).
PE vs Market: HLS is poor value based on its PE Ratio (33.4x) compared to the Australian market (18.5x).
Price to Earnings Growth Ratio
PEG Ratio: HLS is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: HLS is good value based on its PB Ratio (0.9x) compared to the AU Healthcare industry average (1.7x).
Next Steps
Future Growth
How is Healius forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
26.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLS's forecast earnings growth (26.6% per year) is above the savings rate (2.3%).
Earnings vs Market: HLS's earnings (26.6% per year) are forecast to grow faster than the Australian market (10.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HLS's revenue (4.5% per year) is forecast to grow faster than the Australian market (3.6% per year).
High Growth Revenue: HLS's revenue (4.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HLS's Return on Equity is forecast to be low in 3 years time (6%).
Next Steps
Past Performance
How has Healius performed over the past 5 years?
-38.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: HLS's earnings have declined by -38.1% per year over the past 5 years.
Accelerating Growth: HLS's earnings growth over the past year (1263.4%) exceeds its 5-year average (-38.1% per year).
Earnings vs Industry: HLS earnings growth over the past year (1263.4%) exceeded the Healthcare industry 0.3%.
Return on Equity
High ROE: HLS's Return on Equity (2.7%) is considered low.
Return on Assets
ROA vs Industry: HLS's Return on Assets is below or equal to the Healthcare industry average last year.
Return on Capital Employed
ROCE Improving: HLS's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Healius's financial position?
Financial Position Analysis
Short Term Liabilities: HLS's short term assets (A$346.5M) do not cover its short term liabilities (A$391.9M)
Long Term Liabilities: HLS's short term assets (346.5M) do not cover its long term liabilities (903.5M)
Debt to Equity History and Analysis
Debt Level: HLS's debt to equity ratio (39.9%) is considered satisfactory
Reducing Debt: HLS's debt to equity ratio has reduced from 46.9% to 39.9% over the past 5 years.
Debt Coverage: HLS's debt is not well covered by operating cash flow (15.6%).
Interest Coverage: HLS's interest payments on its debt are well covered by EBIT (3.4x coverage).
Balance Sheet
Inventory Level: HLS has a low level of unsold assets or inventory.
Debt Coverage by Assets: HLS's debt is not covered by short term assets (assets are 0.4x debt).
Next Steps
Dividend
What is Healius's current dividend yield, its reliability and sustainability?
2.34%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: HLS's dividend (2.34%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.44%).
High Dividend: HLS's dividend (2.34%) is low compared to the top 25% of dividend payers in the Australian market (5.58%).
Stable Dividend: HLS's dividend payments have been volatile in the past 10 years.
Growing Dividend: HLS's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (78.2%), HLS's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: HLS's dividends in 3 years are forecast to be covered by earnings (51.1% payout ratio).
Next Steps
Management
What is the CEO of Healius's salary, the management and board of directors tenure and is there insider trading?
2.0yrs
Average management tenure
CEO
Malcolm Parmenter (64yo)
2.1yrs
Tenure
AU$1,899,523
Compensation
Dr. Malcolm W. Parmenter, MB, BS, MAICD, has been the Managing Director and Chief Executive Officer at Primary Health Care Limited since September 06, 2017. Dr. Parmenter served as the Chief Executive Offi ...
CEO Compensation Analysis
Compensation vs. Market: Malcolm has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Australian market.
Compensation vs Earnings: Malcolm's compensation has been consistent with company performance over the past year.
Management Age and Tenure
2.0yrs
Average Tenure
Experienced Management: HLS's management team is considered experienced (2 years average tenure).
Board Age and Tenure
4.2yrs
Average Tenure
62yo
Average Age
Experienced Board: HLS's board of directors are considered experienced (4.2 years average tenure).
Insider Trading
Insider Buying: HLS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Non-Executive Director |
| Shares | 15,000 |
| Max Price | AU$3.26 |
| Entity | Company |
| Shares | 2,727,999 |
| Max Price | AU$3.13 |
| Entity | Company |
| Shares | 1,763,938 |
| Max Price | AU$2.88 |
| Entity | Company |
| Shares | 242,481 |
| Max Price | AU$3.00 |
| Entity | Company |
| Shares | 9,500 |
| Max Price | AU$2.96 |
| Entity | Company |
| Shares | 749 |
| Max Price | AU$2.88 |
| Entity | Company |
| Shares | 7,445 |
| Max Price | AU$2.82 |
| Entity | Individual |
| Role | Chairman of the Board Chairman |
| Shares | 25,000 |
| Max Price | AU$3.09 |
| Entity | Company |
| Shares | 135,404 |
| Max Price | AU$2.95 |
| Entity | Company |
| Shares | 2,076 |
| Max Price | AU$2.89 |
| Entity | Company |
| Shares | 4,987 |
| Max Price | AU$2.94 |
| Entity | Company |
| Shares | 193,171 |
| Max Price | AU$2.96 |
| Entity | Company |
| Shares | 1,908,827 |
| Max Price | AU$3.08 |
| Entity | Company |
| Shares | 578,282 |
| Max Price | AU$3.11 |
| Entity | Company |
| Shares | 47,635 |
| Max Price | AU$3.15 |
| Entity | Company |
| Shares | 540,100 |
| Max Price | AU$3.15 |
| Entity | Company |
| Shares | 6,734,836 |
| Max Price | AU$3.10 |
| Entity | Company |
| Shares | 4,115,318 |
| Max Price | AU$2.67 |
| Entity | Company |
| Shares | 3,870,257 |
| Max Price | AU$2.92 |
| Entity | Company |
| Shares | 108,020 |
| Max Price | AU$2.63 |
| Entity | Company |
| Shares | 2,568,130 |
| Max Price | AU$2.80 |
| Entity | Company |
| Shares | 588,414 |
| Max Price | AU$2.97 |
| Entity | Company |
| Shares | 6,826,573 |
| Max Price | AU$2.92 |
| Entity | Company |
| Shares | 4,590,500 |
| Max Price | AU$2.90 |
| Entity | Company |
| Shares | 160,740 |
| Max Price | AU$2.64 |
| Entity | Company |
| Shares | 7,640,319 |
| Max Price | AU$8.11 |
| Entity | Company |
| Shares | 7,982,090 |
| Max Price | AU$3.90 |
| Entity | Individual |
| Role | Member of the Board of Directors Non-Executive Director |
| Shares | 13,080 |
| Max Price | AU$2.25 |
| Entity | Individual |
| Role | Member of the Board of Directors Non-Executive Director |
| Shares | 4,000 |
| Max Price | AU$2.52 |
| Entity | Company |
| Shares | 433 |
| Max Price | AU$2.42 |
| Entity | Company |
| Shares | 148,178 |
| Max Price | AU$2.44 |
| Entity | Company |
| Shares | 6,132,116 |
| Max Price | AU$2.87 |
Ownership Breakdown
Management Team
Malcolm Parmenter (64yo)
MD, CEO & Director
- Tenure: 2.1yrs
- Compensation: AU$1.90m
Tim Haggett
Chief Executive of Medical Centres
- Tenure: 2yrs
- Compensation: AU$935.12k
Dean Lewsam
Chief Executive of Imaging
- Tenure: 4yrs
- Compensation: AU$773.74k
Charles Tilley
Company Secretary
- Tenure: 4.7yrs
Maxine Jacquet
Chief Financial Officer
- Tenure: 0.2yrs
- Compensation: AU$710.97k
Janet Payne
Group Executive of Corporate Affairs
- Tenure: 4.3yrs
John Houston
- Tenure: 2yrs
- Compensation: AU$1.16m
Scott Beattie
Group Executive of Technology & Innovation
- Tenure: 0.8yrs
John McKechnie
Chief Executive of the Pathology Division
- Tenure: 0.2yrs
Alison Stephenson
Additional Company Secretary
- Tenure: 0.2yrs
Board Members
Malcolm Parmenter (64yo)
MD, CEO & Director
- Tenure: 2.1yrs
- Compensation: AU$1.90m
Arlene Tansey (62yo)
Non-Executive Director
- Tenure: 7.2yrs
- Compensation: AU$169.48k
Gordon Davis (63yo)
Non-Executive Director
- Tenure: 4.2yrs
- Compensation: AU$170.68k
Errol Katz (49yo)
Non-Executive Director
- Tenure: 8.9yrs
- Compensation: AU$167.50k
Paul Jones (64yo)
Non-Executive Director
- Tenure: 8.9yrs
- Compensation: AU$157.50k
Rob Hubbard (60yo)
Chairman
- Tenure: 1.3yrs
- Compensation: AU$292.02k
Sally Evans (60yo)
Independent Non-Executive Director
- Tenure: 1.2yrs
- Compensation: AU$134.22k
Company Information
Healius Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Healius Limited
- Ticker: HLS
- Exchange: ASX
- Founded: 1994
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$1.924b
- Shares outstanding: 622.74m
- Website: https://www.healius.com.au
Number of Employees
Location
- Healius Limited
- 203 Pacific Highway
- Level 6
- St Leonards
- New South Wales
- 2065
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PHCR.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jul 1998 |
| HLS | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jul 1998 |
| PGZ | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jul 1998 |
| HLS | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jul 1998 |
Biography
Healius Limited provides various services and facilities to general practitioners, specialists, dentists, IVF specialists, and other healthcare professionals operating in the bulk billing and private billi ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/23 10:31 |
| End of Day Share Price | 2019/10/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.